San Francisco CA | 10th January 2013


Today 10th January 2013, Isogenica, Cambridge UK and  Distributed Bio, San Francisco CA enter into a licence agreement to make next generation antibody libraries available to the life science industry. 

Distributed Bio’s next generation library designs encode years of protein bioengineering and iterative learning, optimised for important characteristics such as stability and immunogenicity, and are designed to provide highly functional antibody libraries with minimal optimisation needs.  These libraries will be manufactured using Isogenica’s Colibra™ technology allowing the synthesis of highly specific, ratio controlled, gene libraries which retain the integrity of library designs and maximise the probability of finding good quality leads.  Isogenica will offer these libraries for discovery projects using either non-proprietary or proprietary selection technologies such as CIS display.
“Our understanding of the requirements for successful biologic medicines has transformed in recent years as a result of the information coming from next generation sequencing.  We are now delighted to be in a position to make these design concepts available to the life sciences industry for therapeutics and diagnostics with Isogenica’s library synthesis technology and their rapid selection and screening tools” said Jacob Glanville, Scientific Director of Distributed Bio.
Notes to Editors
About Isogenica

Isogenica specialises in the discovery and optimisation of therapeutic and diagnostic peptides, proteins and antibodies using its proprietary technology, CIS display.  Founded in 2000, Isogenica has developed a unique capability in the field of protein engineering, with the latest development being the launch of the ColibraTM ratio-controlled gene library synthesis technology for the highly specified construction of antibody and scaffold gene libraries.  Isogenica’s CIS display technology is an in vitro display technology that allows the rapid generation of polypeptide and antibody libraries from which it is possible to rapidly select lead molecules with high affinity and specificity for most targets.